Cellectar Biosciences, Inc. · NASDAQ:CLRB

Cellectar Biosciences — Q1 2024 Earnings Presentation

7 slides from Cellectar Biosciences's earnings presentation, May 14, 2024

  1. Slide 1: First Quarter March 31 2024 Financial Update Call

    First Quarter – March 31 2024 Financial Update Call May 14, 2024 NASDAQ: CLRB

  2. Slide 2: Forward Looking Statements and Disclaimers

    Forward Looking Statements and Disclaimers This presentation contains forward-looking statements. Such statements are valid only as of today and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and u

  3. Slide 3: U.S. Waldenstrom's Macroglobulinemia Market ~$2.1B

    U.S. Waldenstrom’s Macroglobulinemia Market ~$2.1B Market Opportunities to Capture Patient Volume in R/R Market Currently Valued at ~$1.05B 1 2 ~11,500 R/R WM Patients 3L+ Patients not on Active Tx, after 2 prior lines of therapy Existing Relapsed Refractory Market ~1,000 patients have exhausted the

  4. Slide 4: Iopofosine I 131: U.S. WM Shares By Line of Therapy

    Iopofosine I 131: U.S. WM Shares By Line of Therapy No Established Standard of Care Across All Lines of Therapy8 Market Shares by Line of Therapy >60% Non-FDA approved drug share across all lines of therapy 100% 1st Line 2nd Line 3rd Line 4th Line + 12% 13% 17% 18% 3% 1% 3% 1% 4% 4% 4% 52% 22% 3rd l

  5. Slide 5: US Waldenstrom's Macroglobulinemia 3L+ Therapy Details

    US Waldenstrom’s Macroglobulinemia 3L+ Therapy Details Patients often retry prior therapies due to a lack of options, despite suboptimal outcomes 3L+ 3L+ FDA Iopofosine Advantage with Market Patient Market Characteristics Approved Share Counts Potential FDA Approval Bendamustine +/- Rituximab × 10%

  6. Slide 6: Concentrated Patient Volume

    Concentrated Patient Volume Cellectar’s Commercial Strategy to Focus on Key Account Segmentation WM Patient Claim Distribution ~80% Concentrated in 15 states ~70% Treated in 329 accounts ~75% 2nd line + treated in 199 accounts Geographic and Account Segmentation Supports Fast Patient Share Capture i

  7. Slide 7: Supply, Manufacturing and Logistics

    Supply, Manufacturing and Logistics Delivering Convenient Patient-Centric Treatment Patient Centric Radioisotope Supply • Average 12 – 15 min infusion • Isotope readily available from • ~ 30 mins with saline flush multiple sources • Shelf-life provides flexibility in 5 1 • 3 Cellectar validated sour

Cellectar Biosciences — Q1 2024 Earnings Presentation on 6ix